AGIOS PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.60% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-02-12
- AGIOS PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.60%.
- AGIOS PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -2.80%.
- AGIOS PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -2.30%.
- AGIOS PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -3.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 0.60% 10-K · filed 2026-02-12 | |
| 2023-12-31 | -2.80% 10-K · filed 2026-02-12 | |
| 2022-12-31 | -2.30% 10-K · filed 2025-02-13 | |
| 2021-12-31 | -3.90% 10-K · filed 2024-02-15 | |
| 2020-12-31 | -1.60% 10-K · filed 2023-02-23 | |
| 2019-12-31 | -1.90% 10-K · filed 2022-02-24 | -1.30% 10-K · filed 2020-02-19 |
| 2018-12-31 | -0.70% 10-K · filed 2021-02-25 | |
| 2017-12-31 | 0.00% 10-K · filed 2020-02-19 | |
| 2016-12-31 | -0.30% 10-K · filed 2019-02-14 | -0.20% 10-K · filed 2017-02-16 |
| 2015-12-31 | -0.30% 10-K · filed 2018-02-14 | 0.20% 10-K · filed 2016-02-26 |
| 2014-12-31 | -0.10% 10-K · filed 2017-02-16 | -2.10% 10-K · filed 2015-02-24 |
| 2013-12-31 | 0.14% 10-K · filed 2016-02-26 | -1.75% 10-K · filed 2015-02-24 |
| 2012-12-31 | -0.63% 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |